Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Cervical Cancer, September 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 82 articles: HTML format

Single Articles

1. GILLES A, Stevenson E, Thompson J, McMillian-Bohler J, et al
   Enhancing Patient Participation in Follow-Up Care for Cervical Cancer Screening Abnormalities: A Cervical Health Facilitator Pilot Project.
   Nurs Womens Health. 2026 Sep 4:S1751-4851(26)00173.
   PubMed    
   Abstract available
   
   

2. AHN C, Seo H, Jo D, Han B, et al
   Intrathecal Chemotherapy Through Ommaya Reservoir in Leptomeningeal Metastasis From Cervical Cancer: A Rare Case Report and Literature Review.
   J Obstet Gynaecol Res. 2026;52:e70490.
   PubMed    
   Abstract available
   
   

3. NYALAMBISA A, Basera A, Xelwa N, Fadebi O, et al
   Interaction of circular RNAs with splicing factors in cervical cancer: Modulation, interplay and theranostics (Review).
   Mol Med Rep. 2026;34:295.
   PubMed    
   Abstract available
   
   

4. ANGUYO M, Okello MO, Komakec D, Alyoomu E, et al
   Knowledge, Attitudes, and Uptake of Cervical Cancer Screening Among Female Students and Staff at a Tertiary Institution in Northern Uganda: A Cross-Sectional Study.
   Health Sci Rep. 2026;9:e73191.
   PubMed    
   Abstract available
   
   

5. WANG X, Julaiti A, Aisikaer A, Wei H, et al
   Elevated neutrophil extracellular traps formation driven by the HPV-mediated CXCL8-CXCR1/2-ROS-p21 axis promotes the growth and metastasis of cervical cancer.
   Front Immunol. 2026;17:1861481.
   PubMed    
   Abstract available
   
   

6. LI Y, Wang S, Mai Y, You Z, et al
   Efficacy and Safety of Immune Checkpoint Inhibitors for Recurrent or Metastatic Cervical Cancer: A Systematic Review and Meta-Analysis.
   Curr Gene Ther. 2026 Aug 22. doi: 10.2174/0115665232459323260803060556.
   PubMed    
   Abstract available
   
   

7. KOSITAMONGKOL C, Mepramoon E, Kanchanasurakit S, Talungchit P, et al
   Perceived Feasibility and Acceptability of a Self-Collected HPV DNA Testing Policy for Cervical Cancer Screening in Thailand.
   J Prim Care Community Health. 2026;17:21501319261486985.
   PubMed    
   Abstract available
   
   

8. ZHOU YN, Xu FJ, Yao CF, Li Y, et al
   Infection and alpha-ketoglutarate/oxygen inhibition converge to CDC20 to promote cancer cell aneuploidy.
   Signal Transduct Target Ther. 2026;11:364.
   PubMed    
   Abstract available
   
   

9. CHEN J, Kang HY, Jiang YH, Chen CC, et al
   [Mechanism study on baicalein inhibiting cervical cancer driven by persistent HPV infection via restoring MAVS-IRF3-IFN-beta mitochondrial antiviral signal].
   Zhongguo Zhong Yao Za Zhi. 2026;51:4493-4501.
   PubMed    
   Abstract available
   
   

10. NOREEN K, Khalid SN, Noor M, Maryam S, et al
    HPV vaccine uptake in Pakistan: A qualitative study to identify barriers and facilitators before the first HPV national rollout.
    Hum Vaccin Immunother. 2026;22:2721105.
    PubMed    
    Abstract available
    
    

11. HEJCMANOVA K, Ngo O, Chloupkova R, Ambrozova M, et al
    Cancer screening programmes in the Czech Republic and their results.
    Klin Onkol. 2026;39.
    PubMed    
    Abstract available
    
    

12. KOOT J, Kabukye J, Shyamala G, Nazrul N, et al
    Applying an AI Decision Support Device During Cervical Cancer Screening in Bangladesh and Uganda: Implementation Study.
    JMIR Form Res. 2026;10:e81493.
    PubMed    
    Abstract available
    
    

13. KAREKAR AK, Kamat SK, Samant PY, Dandekar SP, et al
    Stage-specific lipidomic signatures as biomarkers in progression of cervical cancer.
    Indian J Med Res. 2026;164:349-356.
    PubMed    
    Abstract available
    
    

14. DESHMUKH VN, Patil SR, Hinge DD, Jadhav PS, et al
    HPV genotype distribution and associated risk factors in women from Karad, Maharashtra: A molecular characterisation study.
    Indian J Med Res. 2026;164:493-495.
    PubMed    
    Abstract available
    
    

15. AHN SY, Yu SY
    Experiences and challenges of North Korean defectors with cervical cancer: a qualitative study using thematic analysis.
    Support Care Cancer. 2026;34:926.
    PubMed    
    Abstract available
    
    

16. GHOSH D, Verma D, Bhimsaria D, Packirisamy G, et al
    Gelatin-PVA Hydrogel Composite-Based Immunosensing Interface for Early Detection of HPV16-Driven Cervical Cancer.
    ACS Appl Bio Mater. 2026 Sep 1. doi: 10.1021/acsabm.6c01028.
    PubMed    
    Abstract available
    
    

17. NAKAJIMA K, Yagi A, Taira K, Otsubo R, et al
    Near-peer education by medical students and its association with HPV vaccination knowledge and attitudes among Japanese adolescents: An exploratory intervention study.
    Hum Vaccin Immunother. 2026;22:2724650.
    PubMed    
    Abstract available
    
    

18. RATHWELL M, Dolin A, Bandara T, Halligan M, et al
    Can we eliminate cervical cancer in Canada? In conversation with leading experts in public health and cancer prevention.
    Can J Public Health. 2026 Sep 2. doi: 10.17269/s41997-026-01247.
    PubMed    
    
    
    

19. DERESE BD, Kantelhardt EJ, Frese T, Ferrell B, et al
    Supportive care needs among patients with breast and cervical cancer at a tertiary cancer treatment center in ethiopia: a cross-sectional study.
    Sci Rep. 2026;16:27555.
    PubMed    
    Abstract available
    
    

20. GUEVARA H, Hcini N, Virjoghe B, Wankpo B, et al
    Cervical cancer in French Guiana before the implementation of the University Hospital: Outcome and prognosis.
    Bull Cancer. 2026 Sep 2:S0007-4551(26)00397-8. doi: 10.1016/j.bulcan.2026.
    PubMed    
    Abstract available
    
    

21. FRANK A, Correa-Mendez M, Livinski AA, Duncan K, et al
    Understanding the association between immune-modulating helminths and HPV or cervical cancer: A scoping review.
    PLoS Negl Trop Dis. 2026;20:e0013308.
    PubMed    
    Abstract available
    
    

22. LI B, Li S, Tan Z, Lin X, et al
    Identification of Risk Factors and Development of a Prediction Model for Postoperative Urinary Retention Following Radical Hysterectomy for Cervical Cancer Based on Preoperative Urodynamic Profiling.
    Arch Esp Urol. 2026;79:1162-1170.
    PubMed    
    Abstract available
    
    

23. MOSQUERA I, Tisler A, Ramirez AT, Elfstrom KM, et al
    Assessing the Capacity of Health Facilities to Deliver Concomitant HPV Vaccination and HPV-Based Cervical Screening Services to Vulnerable Populations - An Implementation Research Protocol.
    Cancer Control. 2026;33:10732748261475365.
    PubMed    
    Abstract available
    
    

24. WU Y, Xue X, Su L, Liu Y, et al
    Correction: Effect of bladder volume on dose of exposure to dangerous organs and incidence of cystitis and enteritis in patients with cervical cancer after external radiotherapy.
    Front Oncol. 2026;16:1959912.
    PubMed    
    Abstract available
    
    

25. LIU H, Wang D, Tang J, Wang C, et al
    Serplulimab combined with bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer (ASTRUM-CC01): a phase II trial.
    Front Immunol. 2026;17:1923961.
    PubMed    
    Abstract available
    
    

26. LIU X, Zheng J, Zhang C, Shi X, et al
    Real-world efficacy and safety profile of low-dose cadonilimab in recurrent or metastatic cervical cancer as first-line therapy.
    Front Immunol. 2026;17:1871890.
    PubMed    
    Abstract available
    
    

27. MENGISTIE N, Verma H, Bozzon A, Bramer WM, et al
    Access to cervical cancer care in sub-Saharan Africa: a narrative review of barriers and opportunities.
    Front Public Health. 2026;14:1881652.
    PubMed    
    Abstract available
    
    

28. WANG H, Zhang G, Wang S, Kong Y, et al
    Virtual MR elastography and continuous-time random walk for predicting Ki-67 status in cervical cancer: a preliminary study.
    Front Oncol. 2026;16:1843126.
    PubMed    
    Abstract available
    
    

29. ZHANG L, Quan R, Huang H, Wang W, et al
    ERalpha36 is associated with SLC7A5/LAT1 expression, cervical cancer progression, and BNCT response: a translational study.
    Front Oncol. 2026;16:1902977.
    PubMed    
    Abstract available
    
    

30. XU Y, Zhou X, Guo L, Lyu R, et al
    DNA Methylation Testing in Cervical Cancer: A Triage Tool for HPV-Based Screening and Post-Treatment Surveillance.
    J Obstet Gynaecol Res. 2026;52:e70473.
    PubMed    
    Abstract available
    
    

31. LIN X, Wang Y, Yu N, Wang D, et al
    HPV Integration as a Triage Tool for HPV-Positive Women in Cervical Cancer Screening.
    Tumour Virus Res. 2026 Sep 1:200351. doi: 10.1016/j.tvr.2026.200351.
    PubMed    
    Abstract available
    
    

32. LI X, Liu X, Ma G, Wang L, et al
    Guardians' willingness to vaccinate primary and secondary school girls against human papillomavirus and associated factors in ethnic autonomous prefectures of Qinghai Province, China: A cross-sectional study based on the Health Belief Model and Theory
    Hum Vaccin Immunother. 2026;22:2725492.
    PubMed    
    Abstract available
    
    

33. MOODALEY P, Lim K, Do V, Descallar J, et al
    Volumetric and Geometric Assessment of Offline Adaptation in Cervical Cancer External Beam Radiotherapy.
    J Med Imaging Radiat Oncol. 2026 Sep 1. doi: 10.1111/1754-9485.70171.
    PubMed    
    Abstract available
    
    

34. AKANNI OA, Yakubu IM, Ojurongbe AO, Fijabiye MO, et al
    Cervical Cancer Screening Utilization and Its Correlates Among Women of Reproductive Age in North Central Nigeria: A Cross-Sectional Study.
    Niger Med J. 2026;67:1463-1472.
    PubMed    
    Abstract available
    
    

35. YANG J, He Q, Peng J, Wang Y, et al
    Artificial intelligence-assisted histopathological diagnosis of endocervical gastric-type adenocarcinoma: a multicenter model development and validation study.
    J Pathol Clin Res. 2026;12:e70113.
    PubMed    
    Abstract available
    
    

36. ZHANG H, Liu A, Zhang R, Wang Y, et al
    Development and Application of a Psychological Expectations Scale for Patients With Middle- and Late-Stage Cervical Cancer in China.
    J Obstet Gynaecol Res. 2026;52:e70481.
    PubMed    
    Abstract available
    
    

37. VON DER BRELIE L, Kalyoncu NG, Gallwas J, Grundker C, et al
    CTGF/CCN2 Promotes Invasive Growth in Cervical Cancer Spheroids and Is Associated With Metastatic Cervical Cancer Tissue.
    Cancer Genomics Proteomics. 2026;23:934-947.
    PubMed    
    Abstract available
    
    

38. TULI A, Jit M, Abbas K, Portnoy A, et al
    Projections of human papillomavirus (HPV) vaccination impact on non-cervical cancer outcomes among women in 117 low- and middle-income countries: a modelling study.
    BMJ Glob Health. 2026;11:e021127.
    PubMed    
    Abstract available
    
    

39. THEODORIDIS TD, Kontovazainitis CG, Negre RR, Argay I, et al
    Complications, recurrence, and survival rates for endometrial and cervical cancer treated by minimally invasive surgery: a systematic review and meta-analysis of randomised controlled trials.
    Facts Views Vis Obgyn. 2026 Aug 31. doi: 10.52054/FVVO.2026.
    PubMed    
    Abstract available
    
    

40. BRUNI L, Brotons M, Alvarez J, Roden RBS, et al
    Developments in human papillomavirus vaccines, schedules, and implementation strategies.
    J Natl Cancer Inst Monogr. 2026;2026:137-147.
    PubMed    
    Abstract available
    
    

41. SIMMS KT, de Bondt D, Killen J, Sy S, et al
    Benefits, harms, and cervical cancer elimination timing of human papillomavirus screening approaches tailored to birth cohort as a proxy for vaccination status in the United States: a comparative modeling study.
    J Natl Cancer Inst Monogr. 2026;2026:126-136.
    PubMed    
    Abstract available
    
    

42. ADSUL P, Adcock R
    From evidence to practice: leveraging implementation science for transitioning to risk-adapted cervical cancer screening.
    J Natl Cancer Inst Monogr. 2026;2026:194-203.
    PubMed    
    Abstract available
    
    

43. ALMONTE M, Tejada RA, Calderon A, Baena A, et al
    Cervical cancer screening in vaccinated populations: challenges and implications for low- and middle-income countries.
    J Natl Cancer Inst Monogr. 2026;2026:155-163.
    PubMed    
    Abstract available
    
    

44. BONDE J, Castle PE
    Deintensification of cervical cancer screening in the era of high human papillomavirus-vaccination coverage.
    J Natl Cancer Inst Monogr. 2026;2026:173-179.
    PubMed    
    Abstract available
    
    

45. WENTZENSEN N, Arbyn M, Poljak M
    How to evaluate and select cervical screening and triage tests in vaccinated populations.
    J Natl Cancer Inst Monogr. 2026;2026:164-172.
    PubMed    
    Abstract available
    
    

46. BASU P, Lucas E, Elfstrom KM
    How practically feasible is tailored screening for cervical cancer based on human papillomavirus vaccination status?: the role of data linkage and registers.
    J Natl Cancer Inst Monogr. 2026;2026:180-186.
    PubMed    
    Abstract available
    
    

47. WALLER J, Marlow L
    Effective communications to support risk-adapted cervical screening in human papillomavirus-vaccinated women: lessons learned and ways forward.
    J Natl Cancer Inst Monogr. 2026;2026:187-193.
    PubMed    
    Abstract available
    
    

48. EL-ZEIN M, Franco EL
    The need to change cervical cancer screening in the post-human papillomavirus vaccination era: the interplay between disease prevalence and risk, test characteristics, and efficiency of screening programs.
    J Natl Cancer Inst Monogr. 2026;2026:118-125.
    PubMed    
    Abstract available
    
    

49. GRAY P, Louvanto K
    Evidence for type replacement as a consequence of vaccination and implications for cervical screening.
    J Natl Cancer Inst Monogr. 2026;2026:148-154.
    PubMed    
    Abstract available
    
    

50. DE AZEVEDO VR, Guimaraes IDS, Farrapo MJS, Martins-Cardoso K, et al
    EGFR and PGE2 signaling pathways mutually cooperate to promote pro-tumorigenic effects in cervical cancer.
    Biochim Biophys Acta Mol Basis Dis. 2026;1873:168443.
    PubMed    
    Abstract available
    
    

51. HAO S, Yang S, Zhao Q, Jiang L, et al
    Charting host structural variations in cervical cancer by long-read sequencing pinpoints a functional deletion in PIAS1.
    Genomics. 2026;118:111311.
    PubMed    
    Abstract available
    
    

52. WU T, Lv B, Wang H, He G, et al
    Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer.
    Bioact Mater. 2026;67:703-718.
    PubMed    
    Abstract available
    
    

53. OZKAYA UCAR Y, Turan T
    Postoperative Sexual Quality of Life and Associated Factors After Loop Electrosurgical Excision Procedure Versus Cold Knife Conization in 185 Sexually Active Women With Preinvasive Cervical Lesions.
    Med Sci Monit. 2026;32:e954246.
    PubMed    
    Abstract available
    
    

54. GHOLAMI FASHKHAMI M, Habibollahi H, Shafighi ST
    Chrysin treatment is associated with altered microrna expression and reduced levels of HPV16 E6 protein in caski cervical cancer cells.
    Med Oncol. 2026;43:257.
    PubMed    
    Abstract available
    
    

55. RAO S, Chhabra M, Kudkuli J, Toraskar M, et al
    Integrating a "see-and-treat" approach with opportunistic human papilloma virus deoxyribonucleic acid (HPV DNA) based cervical cancer screening in India: a retrospective cross-sectional study.
    AJOG Glob Rep. 2026;6:100678.
    PubMed    
    Abstract available
    
    

56. ZHENG Y, Li Y, Zhang S, Lv Q, et al
    Transcriptomics and single-cell RNA sequencing uncover prognostic characteristics and immune regulatory mechanisms of lactylation in cervical cancer.
    Bioimpacts. 2026;16:33527.
    PubMed    
    Abstract available
    
    

57. IBITOYE OF, Muliira JK, Lazarus ER, Anyango JF, et al
    Nurse-led interventions for cervical cancer patients: A scoping review with an emphasis on East Asian contexts.
    Belitung Nurs J. 2026;12:424-437.
    PubMed    
    Abstract available
    
    

58. WANG W, Yu T
    The implications and mechanisms of vaginal microbiota metabolites on cervical cancer progression.
    Front Cell Infect Microbiol. 2026;16:1886165.
    PubMed    
    Abstract available
    
    

59. HUANG Q, Zhang LY, Shu HL, Chen N, et al
    Cervical cancer patients' vaginal microbiome and metabolites: research progress and clinical applications.
    Front Microbiol. 2026;17:1891111.
    PubMed    
    Abstract available
    
    

60. CHALIF J, Morton M, McLaughlin E, Fulton J, et al
    Prognostic value of the nutritional risk index and prognostic nutritional index for immunotherapy outcomes in cervical Cancer.
    Gynecol Oncol Rep. 2026;67:102184.
    PubMed    
    Abstract available
    
    

61. LI X, Fan X, Chai T, Hu L, et al
    HPV52 predominates in cervical infections and precancerous lesions in Chongqing, China: a 6-year study linking genotypes to vaginal microecology.
    Front Public Health. 2026;14:1879232.
    PubMed    
    Abstract available
    
    

62. DIAW AM, Diongue FB, Ndiaye I, Gassama O, et al
    Women's autonomy and discrimination relevant to cervical cancer screening.
    Front Reprod Health. 2026;8:1837034.
    PubMed    
    Abstract available
    
    

63. MIAO S, Guan W, Jiang W, Zhang B, et al
    High diagnostic concordance between vulvar and cervical samples for human papillomavirus detection: a cross-sectional study.
    Microbiol Spectr. 2026;14:e0402625.
    PubMed    
    Abstract available
    
    

64. JIA Q, Li M, Liu J, Xu T, et al
    CLCF1-ZIC5-CNTFR feedback loop drives cisplatin resistance in cervical squamous cell carcinoma.
    Neoplasia. 2026;80:101342.
    PubMed    
    Abstract available
    
    

65. GONG J, Dong S, Sun J, Cong M, et al
    Effects of a Message-Framing Video Intervention on Maternal Vaccine Confidence Regarding HPV Vaccination for Daughters: A Quasi-Experimental Study Among Mothers With Cervical Intraepithelial Neoplasia.
    Public Health Nurs. 2026;43:1316-1325.
    PubMed    
    Abstract available
    
    

66. ERSOY E, Gursoy A, Guder H
    Evaluating the cost-effectiveness of implementing HPV vaccination in Turkiye's National Immunization Program using the PRIME model.
    Ginekol Pol. 2026;97:641-646.
    PubMed    
    Abstract available
    
    

67. FELDMAN C, Semprini J
    Causal inference, cancer registry data, and a single state policy change: Evaluating Virginia's HPV vaccine mandate.
    J Cancer Policy. 2026;49:100777.
    PubMed    
    Abstract available
    
    

68. BRUNEAU N, Balanda M, Martin HS, Munoz T, et al
    The prevalence of human papillomavirus infection among women in primary health care, Santiago, Chile (2015-2024).
    J Cancer Policy. 2026;49:100776.
    PubMed    
    Abstract available
    
    

69. ABOUL-ENEIN BH, Kelly PJ, Almoayad F, Keller T, et al
    Promoting the HPV vaccine across the league of Arab states: A scoping review of interventions.
    J Cancer Policy. 2026;49:100770.
    PubMed    
    Abstract available
    
    

70. GAO T, Kabila PM, Chiuri K, Tumba AM, et al
    Costs of HPV vaccination programs in low- and middle-income countries: A systematic review.
    J Cancer Policy. 2026;49:100767.
    PubMed    
    Abstract available
    
    

71. CROCKER RM, Schneider JL, Rivelli JS, Gautom P, et al
    Comparative Analysis of Breast and Cervical Screening Adaptability at a Federally Qualified Health Center.
    Cancer Prev Res (Phila). 2026;19:529-540.
    PubMed    
    Abstract available
    
    

72. KURT GUVEN H, Tunc T, Celik Inaltun CB, Asker L, et al
    The Effect of Breastfeeding on Cervical Dysplasias.
    Breastfeed Med. 2026;21:541-547.
    PubMed    
    Abstract available
    
    

73. EJAZ M, Khan MS, Baig AQ, Hussain S, et al
    Dosimetric Comparison of Fixed-Configuration Versus Image Guided Needle Insertion in Cervical Brachytherapy.
    Pract Radiat Oncol. 2026;16:e427-e434.
    PubMed    
    Abstract available
    
    

74. WOODRUFF JAMESON A, Kelley C, Westmark D, Willett S, et al
    Interventions to increase cervical screening rates for women with intellectual and developmental disabilities: a scoping review.
    J Intellect Dev Disabil. 2026;51:350-360.
    PubMed    
    Abstract available
    
    

75. MASHELE S, Nethavhakone N, Mohlala M, Ayeni P, et al
    Turnaround Time Trends in Cervical Cytology Screening in South Africa, 2005-2023.
    Diagn Cytopathol. 2026;54:755-763.
    PubMed    
    Abstract available
    
    

76. BEKKEVOLD T, Laake I, Feiring B, Soreng K, et al
    HPV Genotype Distribution in Cervical Cancer and High-Grade Lesions in Norway, and Early Vaccine Impact.
    Int J Cancer. 2026 Aug 28. doi: 10.1002/ijc.70712.
    PubMed    
    Abstract available
    
    

77. MORA-SOTO N, Viveros-Carreno D, Peralta JA, Rodriguez J, et al
    Diagnostic accuracy of Chronic Kidney Disease Epidemiology Collaboration 2021 and Janowitz-estimated glomerular filtration rate for identifying renal dysfunction compared with 99mTc-DTPA in patients with locally advanced cervical cancer.
    Int J Gynecol Cancer. 2026 Aug 13:104969. doi: 10.1016/j.ijgc.2026.104969.
    PubMed    
    Abstract available
    
    

78. JORDAN SE, Gonzalez-Martin A, Morlock R, Hubig L, et al
    Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.
    Int J Gynecol Cancer. 2026 Aug 11:104947. doi: 10.1016/j.ijgc.2026.104947.
    PubMed    
    Abstract available
    
    

79. CHEN YN, Yang XL, Zhu JW, Zhou YC, et al
    Application of small-pelvic adjuvant radiotherapy in early cervical cancer without high-risk factors after hysterectomy.
    Int J Gynecol Cancer. 2026 Aug 29:104952. doi: 10.1016/j.ijgc.2026.104952.
    PubMed    
    Abstract available
    
    

80. LUO H, Yang M, Li J, Qiu T, et al
    Toward Optimal Fractionation Schemes in Non-uniform Radiotherapy: Exploiting Helical Tomotherapy's Thread Effect for Gynecological Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2026 Mar 24:S0360-3016(26)00508.
    PubMed    
    Abstract available
    
    

81. BRUNO MT, Pagana A, Aiello T, Pivetti E, et al
    Is active surveillance of CIN2 always appropriate? Clinical outcomes and factors associated with progression and regression over 48 months in an HPV-positive cohort.
    BMC Cancer. 2026 Jun 22. doi: 10.1186/s12885-026-16398.
    PubMed    
    Abstract available
    
    

82. MOUCHERAUD C, Fan B, Li G, Ochieng E, et al
    Understanding retention in longitudinal surveys conducted by mobile phone in lower-resource contexts: A case study from Kenya.
    PLoS One. 2026;21:e0354780.
    PubMed    
    Abstract available